ALEFACEPT

ALEFACEPT Struktur
CAS-Nr.
Englisch Name:
ALEFACEPT
Synonyma:
ALEFACEPT
CBNumber:
CB9749748
Summenformel:
Molgewicht:
0
MOL-Datei:
Mol file

ALEFACEPT Eigenschaften

Sicherheit

ALEFACEPT Chemische Eigenschaften,Einsatz,Produktion Methoden

Verwenden

Treatment of plaque psoriasis.
Alefacept (Amevive) is a fully human lymphocyte function–associated antigen 3/immunoglobulin 1 (LFA-3/IgG1) fusion protein. It binds to CD2 on T cells, inhibiting T-cell activation and producing selective T-cell apoptosis. Alefacept is FDA approved as a 12-week course of 15 mg weekly intramuscular injections. Long remissions can be seen in responders. Peripheral CD4 counts should be followed and doses withheld if counts drop below 250 cells/μL. Therapy should be discontinued if the CD4 count remains below 250 cells/μL for >4 weeks. A second course lengthens the period of remission without additional toxicities.

Enzyminhibitor

This recombinant immunosuppressive protein (FW = 51800 g/mol; CAS 222535-22-0), marketed under the trade name Amevive?, reduces the number of psoriasis-associated T lymphocytes, thereby alleviating an underlying cause of the disorder. Alefacept is indicated in patients with moderate to severe chronic plaque psoriasis. The dimeric fusion protein consists of the extracellular CD2-binding portion of the human Leukocyte Function Antigen-3 (or LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Amevive is a fully humanized toxin that binds to CD2 and blocks costimulatory signaling, selectively inducing apoptosis of activated memory T cells involved in the pathogenesis of psoriasis. Alefacept has a slow onset of action, peaking approximately 18 weeks after the first injection of a 12-week course. Because psoriasis is a chronic disorder, patients require lifelong access to injectable biologic agents targeting specific immune mediators, raising concerns about their longterm safety. Alefacept is only effective in a small proportion of patients, and its maximal efficacy is not achieved until 4-6 weeks after a treatment course.

ALEFACEPT Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


ALEFACEPT Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 4)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
ecochem international chemical broker --
export@ecochem.dk Europe 6385 66
kemikalieimport --
Sales@kemikalieimport.dk Europe 6699 47
A.T.CHEMICAL --
Jeffreyxu@atchem.net China 6594 51
QVENTAS INC. --
mike@qventas.com United States 383 47

  • ALEFACEPT
Copyright 2019 © ChemicalBook. All rights reserved